<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="342992">
  <stage>Registered</stage>
  <submitdate>30/05/2011</submitdate>
  <approvaldate>1/06/2011</approvaldate>
  <actrnumber>ACTRN12611000555954</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of Silodosin in Expulsive Therapy of Lower Ureteral Stones: A Randomized Controlled trial</studytitle>
    <scientifictitle>Efficacy of silodosin in expulsive therapy of lower ureteral stones</scientifictitle>
    <utrn>U1111-1121-8109</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>lower ureteral stones</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>silodosin (4 mg daily) orally for 2 weeks</interventions>
    <comparator>lactose tablet orally daily for 2 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>the expulsion time</outcome>
      <timepoint>reported by patient within 2 weeks or Stone presence and characteristics were diagnosed through x-ray of kidney-ureter-bladder, abdominal ultrasonography, intravenous urography and nonenhenced CT 2 weeks later</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>the expulsion rate</outcome>
      <timepoint>Stone presence and characteristics were diagnosed through x-ray of kidney-ureter-bladder, abdominal ultrasonography, intravenous urography and nonenhenced CT 2 weeks later</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>analgesic consumption</outcome>
      <timepoint>(All patients were prescribed ketorolac 10 mg three time per day for analgesic use and allowed to use sublingual buprenorphine 0.2 mg on demand) recorded by patient diaries in2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>lower urinar tract symptoms</outcome>
      <timepoint>Questionrire (IPSS) 2 weeks later</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>colic episodes</outcome>
      <timepoint>recorded by patient diaries in 2 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with radiopaque lower ureteral stones&gt;5mm</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>urinary tract infections, high-grade hydronephrosis, diabetes, ulcers, or a history of hypersensitivity toa-1 blocker and pregnant women were excluded. Patients with a history of spontaneous stone expulsion, hypotension, or those found to have systolic blood pressure lower than 110 mmHg</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>random number table</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2010</anticipatedstartdate>
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate>31/12/2011</anticipatedenddate>
    <actualenddate>31/12/2011</actualenddate>
    <samplesize>55</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Taiwan, Province Of China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Chung Jing Wang</primarysponsorname>
    <primarysponsoraddress>60058 No 565 2nd Ta-Ya Rd Chia-Yi city, Taiwan,ROC
St. Martin De Porres Hospital</primarysponsoraddress>
    <primarysponsorcountry>Taiwan, Province Of China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Chung Jing Wang</fundingname>
      <fundingaddress>60058 No 565 2nd Ta-Ya Rd Chia-Yi city, Taiwan,ROC
St. Martin De Porres Hospital</fundingaddress>
      <fundingcountry>Taiwan, Province Of China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>perform a comparative study to evaluate the clinical role of silodosin in the medical expulsive therapy of symptomatic lower ureteral stones.</summary>
    <trialwebsite />
    <publication>not yet </publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>STM IRB</ethicname>
      <ethicaddress>60058 No 565 2nd Ta-Ya Rd Chia-Yi city Taiwan,ROC
St. Martin De Porres Hospital</ethicaddress>
      <ethicapprovaldate>15/04/2010</ethicapprovaldate>
      <hrec>IRB-STM-2010-012</hrec>
      <ethicsubmitdate>11/03/2010</ethicsubmitdate>
      <ethiccountry>Taiwan, Province Of China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd Ta-Ya Rd Chia-Yi city, Taiwan,ROC
St. Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax>886-5-2788535</fax>
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd Ta-Ya Rd Chia-Yi city, Taiwan,ROC
St. Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax>886-5-2788535</fax>
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd Ta-Ya Rd Chia-Yi city, Taiwan,ROC
St. Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax>886-5-2788535</fax>
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chung Jing Wang</name>
      <address>60058 No 565 2nd Ta-Ya Rd Chia-Yi city, Taiwan,ROC
St. Martin De Porres Hospital</address>
      <phone>886-5-2756000-1013</phone>
      <fax>886-5-2788535</fax>
      <email>jing@stm.org.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>